your market intelligence analyst
Search Results
566 results
Your search is now limited to «Lung Cancer» expert search.
lncRNA LEF1-AS1 Promotes Proliferation and Induces Apoptosis of Non-Small-Cell Lung Cancer Cells by Regulating miR-221/PTEN Signaling.
More from International Journal of COPD: 05/22/2020 19:23
Condition : Non Small Cell Lung Cancer Intervention : Drug: TQ-B3139 Sponsor : Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting.
More from 05/22/2020 16:40
Takeda Pharmaceutical Co Ltd:
More from
FP Trading Desk (Canada) 05/22/2020 16:30
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases CAMBRIDGE, Mass. & OSAKA, Japan — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) [...]
More from FP Trading Desk (Canada):
European Respiratory Journal 05/22/2020 09:03
Purpose. HIV infection is an exclusion criterion in lung cancer trials. This multicenter phase II trial aimed to assess feasibility, efficacy and safety of first-line carboplatin plus pemetrexed (CaP) followed by pemetrexed ℗ maintenance in people living with HIV (PLHIV) with advanced non-squamous non-small cell lung cancer (NS-NSCLC). Methods. Four cycles of CaP were followed by P-maintenance therapy in patients with Eastern Cooperative Oncology Group performance status (PS) ≤2. The primary objective was a disease control rate (DCR) ≥30% after 12 weeks. Results. Of the 61 PLHIV enrolled 49 (80%) had a PS 0–1, 19 (31%) brain metastases. Median CD4 lymphocyte count was 418 cells·µL –1 (range: 18–1230), median CD4 lymphocyte nadir 169.5 cells·µL.
Cancer Network 05/22/2020
In order to address the knowledge gap, the International Association for the Study of Lung Cancer (IASLC) conducted an international survey to assess current practices and possible barriers to molecular testing.
More from Cancer Network:
Onclive 05/19/2020 11:46
Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.
More from Onclive:
GlobeNewswire 05/19/2020 01:00
FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer Swiss Stock Exchange:RO.
More from GlobeNewswire:
Therefore, it can be speculated that colorectal cancer is more likely to metastasize to the lung than breast cancer, and breast cancer is more likely to metastasize to the lung in the Chinese population than in others.
More from Diagnostic Pathology - Abstract:
Cancer Cell International 05/18/2020 20:00
Microarray profiles reveal that circular RNA hsa_circ_0007385 functions as an oncogene in non-small cell lung cancer tumorigenesis.
More from Cancer Cell International:
Healio News 05/18/2020 17:32
FDA expands Tecentriq approval for metastatic lung cancer.
More from Healio News:
The US Food and Drug Administration (FDA) approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with certain lung cancers.
More from RT: For Decision Makers in Respiratory Care:
People with lung conditions 'should NOT wear face masks if it makes it hard to breathe'.
More from Mail on Sunday (United Kingdom):
Business Wire 05/18/2020 15:30
About lung cancer According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2020, and NSCLC accounts for 80-85% of all lung cancers.
More from Business Wire:
PubMed News (NIH) 05/18/2020
Status Public on May 18, 2020 Title FAM111B contributes to the growth of lung adenocarcinoma with KRAS mutation by degrading p16 and promoting cell cycle.
More from PubMed News (NIH):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications